Canaccord Genuity analyst Kyle Rose maintained a Hold rating on Nuvasive on Wednesday, setting a price target of $57, which is approximately 2.50% below the present share price of $58.46.
Rose expects Nuvasive to post earnings per share (EPS) of $0.11 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in NuVasive (NASDAQ:NUVA), with an average price target of $61.25.
The analysts price targets range from a high of $74 to a low of $48.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $295.28 million and a net profit of $30.16 million. The company's market cap is $3 billion.
According to TipRanks.com, Canaccord Genuity analyst Kyle Rose is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.3% and a 59.49% success rate.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.